GYNECOLOGICAL

Code	Status	Phase	Title
2015-005137-42		II	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer.
2015-000734-30		IV	An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (ORZORA)
2013-001472-38		Ib/II	PiSARRO: p53 suppressor activation in recurrent hit grade Serous ovarian cancer, a phase Ib/II study of systemic carboplatin combination chemotherapy with or without APR-246
2015-000952-11		III	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
2017-000265-67		II	PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246sistémica pegilada con APR-246.
2016-003346-90		IIIb	A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
2015-004844-20		III	Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)